Renal Transplantation Clinical Trial
Official title:
Study of the Impact of VEGF Polymorphism on the Development of Renal Carcinoma in Renal Transplant Patients
Renal transplant patients have on average 3-5 times more risk of developing cancer than the
general population. This rate can be increased up to 10 to 15 times in some type of cancer
like kidney cancer. Among the identified risk factors, immunosuppressants and, in
particular, calcineurin inhibitors (ciclosporin and tacrolimus) play a major role in
increasing cancers apart from their depressant effects on the immune system.
Calcineurin inhibitors (CCN) are the basis of immunosuppressive therapy in renal
transplantation. Several mechanisms have been implicated to explain their pro-oncogenic
properties. One related to an increase in VEGF expression seems particularly interesting in
the study of renal cell carcinoma in the transplanted patient. Indeed, the physiopathology
of kidney cancer has clearly been associated with an increase in the production of VEGF.
Furthermore, some polymorphisms of the gene encoding VEGF have already been associated with
the survival of patients with renal carcinoma and the circulating level of VEGF in the
general population. The search for an association between the polymorphisms of the VEGF gene
and renal carcinoma in renal transplant patients could thus identify patients whose risk of
renal cell carcinoma (cRCC) post-transplantation is increased. If the involvement of certain
polymorphisms in the development of cRCC was confirmed in this population, their research
before the introduction of the immunosuppressive treatment would make it possible to direct
the choice of treatment towards molecules without pro-oncogenic property in the Patients
such as mTOR protein inhibitors (sirolimus, everolimus). This research project is therefore
in line with the desire to move towards a more "personalized" medicine that could be
beneficial for the patient.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06026592 -
Detection of Plasma DNA of Renal Origin in Kidney Transplant Patients
|
||
| Active, not recruiting |
NCT02444429 -
3-month Screening Biopsy to Optimize the Immunosuppression in Renal Transplantation
|
Phase 3 | |
| Completed |
NCT02238418 -
Efficacy of Usual Vitamin D Supplementation and Its Impact on Children and Adolescents Calciuria.
|
Phase 4 | |
| Completed |
NCT01729494 -
Belatacept Early Steroid Withdrawal Trial
|
Phase 4 | |
| Terminated |
NCT01436305 -
Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation
|
Phase 2 | |
| Terminated |
NCT01276834 -
Comparison of Immunosuppression on Progression of Arteriosclerosis in Renal Transplantation
|
Phase 4 | |
| Completed |
NCT02843295 -
Catalytic Antibodies to Predict Uninvasively Late Transplant Failure
|
N/A | |
| Completed |
NCT00842699 -
Characterization of Immunological Profile of Renal Transplant Patients Undergoing Induction Treatment With Thymoglobulin vs. IL-2 Receptor Antagonist Basiliximab
|
N/A | |
| Completed |
NCT00525681 -
Interaction Between Rimonabant and Cyclosporine and Tacrolimus
|
Phase 4 | |
| Completed |
NCT00776750 -
Influenza Vaccination in Hemodialysis Patients and Renal Transplant Recipients
|
Phase 4 | |
| Completed |
NCT00189735 -
A Study to Evaluate FK778 in Kidney Transplant Patients
|
Phase 2 | |
| Recruiting |
NCT04052867 -
Intravenous Lignocaine Infusion in Laparoscopic Donor Nephrectomy
|
N/A | |
| Completed |
NCT02587052 -
A 1-year Comparison of Generic Tacrolimus (Tacni) and Prograf in Renal Transplant Patients - a Retrospective Matched Pair Analysis, GenTac
|
||
| Completed |
NCT02020642 -
Effect of Renal Transplantation on Obstructive Sleep Apnea in End Stage Renal Disease Patients (SASinTx)
|
N/A | |
| Completed |
NCT01435291 -
AADAPT - Analysis of Advagraf Dose Adaptation Post Transplantation
|
Phase 4 | |
| Recruiting |
NCT01001065 -
Association of the Intrarenal Resistance Index (RI) of Transplanted Kidneys With Generalized Atherosclerosis
|
N/A | |
| Completed |
NCT00978965 -
Identification of Patients With High Probability of Poorly Responding to Therapy With Mycophenolic Acid Prodrugs
|
||
| Recruiting |
NCT00903188 -
Calcineurin Inhibitor (CNI) Versus Steroid Cessation in Renal Transplantation
|
Phase 4 | |
| Completed |
NCT00425308 -
Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.
|
Phase 3 | |
| Completed |
NCT00400400 -
Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) Intolerance
|
Phase 4 |